Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape

Key opinion leaders provide a concise overview of the atopic dermatitis (AD) treatment landscape, focusing on the role of topical therapy, and highlight the current unmet needs in AD management.

EP: 1.Tackling Key Concerns in Atopic Dermatitis + Biologic Use

Now Viewing

EP: 2.Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape

EP: 3.Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment

EP: 4.Experts Discuss Long-Term Effects and Monitoring in AD Therapy

EP: 5.Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

EP: 6.The Patient Journey: Effectively Managing AD Itch Early On

EP: 7.Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies

EP: 8.Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care

1. Provide a brief overview of the treatment landscape, and where topical therapies and systemic therapies fit into this landscape. What are the current unmet needs from your perspective?
2. Please incorporate a discussion of the following topical therapies:
3. Corticosteroids
4. Crisaborole – AD-301/AD-302, CrisADe CARE 1 
5. Ruxolitinib – TRuE-AD1/TRuE-AD2 – original publication, long-term follow up

Related Videos

Related Content

Advertisement

July 31st 2025

High Adenoma Detection Rates Linked to Lower CRC Rates, Worse Survival

Pearl Steinzor

In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.

July 31st 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 31st 2025

Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL

Laura Joszt, MA

Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.

July 31st 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 31st 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 31st 2025

FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older

Brooke McCormick

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).

Related Content

Advertisement

July 31st 2025

High Adenoma Detection Rates Linked to Lower CRC Rates, Worse Survival

Pearl Steinzor

In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.

July 31st 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 31st 2025

Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL

Laura Joszt, MA

Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.

July 31st 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 31st 2025

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

AJMC Contributor

Real-world data support the effectiveness of combining platinum-based chemotherapy with PD-1 inhibitors for recurrent limited-disease small cell lung cancer (SCLC), enhancing patient outcomes.

July 31st 2025

FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older

Brooke McCormick

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).